title: Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
authors.affiliation: Department of Dermatology, Columbia University, College of Physicians and Surgeons, 150 West 55th Street, New York, NY 10019, USA. scheinfeld@earthlink.net
authors.forename: Noah S
authors.initials: NS
authors.lastname: Scheinfeld
mesh_terms: D000279:Administration, Cutaneous; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001623:Betamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002117:Calcitriol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D012536:Scalp Dermatoses / Q000188:drug therapy* / Q000473:pathology; D013535:Suspensions
chemical_list: D000893:Anti-Inflammatory Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; D013535:Suspensions; C517164:betamethasone dipropionate, calcipotriol drug combination; D001623:Betamethasone; D002117:Calcitriol